The drug company behind tirzepatide — and what the clinical evidence actually shows

How Lilly's research led to a dual-receptor medicine, and why that matters

Eli Lilly's scientists spent years investigating the gut hormones GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) before arriving at tirzepatide. Earlier GLP-1 medicines, including semaglutide, target a single pathway. Lilly's approach was to build one molecule that activates both receptors, each of which plays a role in appetite signalling, stomach emptying and blood-sugar regulation. The hypothesis was that dual activation might produce greater weight loss than either pathway alone.

The evidence supports that hypothesis. In the SURMOUNT-1 trial (2,539 adults with obesity, no diabetes) participants taking 15mg tirzepatide lost around 20–21% of body weight on average over 72 weeks, according to the SURMOUNT-1 paper published in the New England Journal of Medicine. That figure comes from a randomised, controlled trial, not a marketing claim. NICE's committee reviewed the same data and noted that indirect comparisons favoured tirzepatide over semaglutide 2.4mg, a conclusion later reinforced by the head-to-head SURMOUNT-5 trial, published in the NEJM in 2025.

Lilly holds authorised supplier relationships with the UK licensed supply chain. When you receive Mounjaro through a GPhC-registered UK pharmacy, it arrives from that authorised channel, not from a grey market or unverified source. That distinction matters more than it might seem, given the MHRA's ongoing enforcement action against counterfeit pens sold online.

What the NICE recommendation actually says about tirzepatide's licensed use

NICE published technology appraisal TA1026 on 23 December 2024, recommending tirzepatide for adults with a BMI of 35 or above and at least one weight-related comorbidity. Thresholds are set 2.5 kg/m² lower for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. NHS implementation is being phased, details of who qualifies at each stage of the rollout are explained on the tirzepatide overview page.

The licensed private-prescription criteria are slightly broader than the NHS pathway: a BMI of 30 or above, or 27 with a relevant condition such as hypertension, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. BMI alone does not determine approval, the prescriber assesses the full clinical picture, including current medicines, medical history and any contraindications listed in the SmPC.

If you want a fuller picture of what the drug tirzepatide is, how it works pharmacologically, and what its authorised indications cover, that detail is set out on a dedicated page. Tirzepatide carries the Black Triangle (▼) designation, which Lilly and the MHRA agreed as part of the UK authorisation. This does not imply a problem, it is standard for newer medicines and triggers enhanced pharmacovigilance. It means any suspected side effect, however minor, can be reported to the MHRA via the Yellow Card scheme.

To understand how Mounjaro fits into the broader private-treatment landscape, the weight-loss treatments page sets out current pricing context and what a clinical consultation involves.

Eli Lilly in the UK: supply chain, pricing and what it means for patients

Lilly manufactures Mounjaro as a once-weekly subcutaneous KwikPen, each pen contains four weekly doses at the prescribed strength. UK strengths run from 2.5mg up to 15mg, escalating in steps that a prescriber sets based on tolerability and clinical response. The first pen's purpose is to let the body adjust; therapeutic effect builds over the titration period. Most people keep their pen in the fridge door rather than the main shelf, away from ice-packs and temperature fluctuations, but the exact storage window is specified in the Patient Information Leaflet, and the leaflet takes precedence over any general advice.

Lilly announced a UK list-price increase from 1 September 2025, and typical private prices since then have ranged roughly £149–£375 per month depending on dose and provider, as widely reported. These figures shift the conversation that patients and pharmacies have about value: what is included alongside the medicine, and how robust is the clinical oversight? For more on how to read a medicine's cost realistically, there is a practical breakdown on the Mounjaro information page.

Lilly sources for the UK operate through the licensed supply chain; questions about a specific pharmacy's supplier relationships are answered by the pharmacy's GPhC registration and dispensing records. If you are weighing up providers, our guidance on choosing the best tirzepatide peptide company for quality, safety and clinical oversight explains what to look for. Anyone curious about how to check whether an online pharmacy is legitimate can search the GPhC register, a five-second check that is the strongest single safeguard when buying a prescription medicine online.

From Lilly's data to a clinical decision about you

Lilly's research programme generated the evidence; it does not make individual clinical decisions. That is the prescriber's role. At nume, every consultation is personally read the same day by a GPhC-registered Independent Prescriber, a named clinician who considers your answers, your medical history and your current medicines before deciding whether tirzepatide is clinically suitable. There is no automated approval pathway. If you are already on treatment elsewhere and considering a transfer, our clinical team asks for evidence of your current dose before any continuation.

The question of which company makes Mounjaro, or what company manufactures tirzepatide, is a reasonable starting point, knowing who stands behind a medicine is part of due diligence. Background on the Mounjaro company, its history and its role in the UK supply chain is available if you want to explore that further. The next step is understanding whether that medicine is clinically right for you, and that is a question for a prescriber, not a webpage. Our clinical team profile sets out who will be reviewing your consultation.